Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-sunflower in ER+/HER2+ Advanced Breast Cancer
NCT05577923Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Nov 2022
- Primary completion
- Sep 2024
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, pyrotinib, dalpiciclib and fulvestrant in breast cancer, sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 5 years. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05577923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05577923.